ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership

At the ARVO meeting, Zeiss will spotlight its ongoing research collaboration with Boehringer Ingelheim and its new research platform. Image credit: ©Arsenii – stock.adobe.com

Carl Zeiss Meditec AG has introduced its new Zeiss Research Data Platform (ZEISS RDP), a cloud-based, AI-driven solution designed to transform ophthalmic research workflows. A full introduction will be conducted at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting.

Euan S. Thomson, PhD, head of the digital business unit for Zeiss Medical Technology, commented on ZEISS RDP in a press release from the company ahead of ARVO.¹

"The future of healthcare is in the data. At Zeiss, we are delivering digital innovation to help shape the future of ophthalmology, investing in research methods that empower clinicians and researchers in balancing their clinical care and research requirements," said Thomson. "The introduction of the ZEISS RDP reflects our commitment to advancing ophthalmic care through smarter, AI-powered tools."

The ZEISS RDP “enables seamless integration of clinical and research data and empowers clinicians and scientists to accelerate discoveries through smarter, more efficient research.”

At the ARVO meeting, Zeiss will also spotlight its ongoing research collaboration with Boehringer Ingelheim, which focuses on precise, personalised ophthalmic interventions. Two expert talks at the Zeiss booth during ARVO will share insights on applications of artificial intelligence in the near future.

"At Boehringer Ingelheim, we’re working toward a future in which earlier detection and intervention result in long-term, real-world outcomes that prevent vision loss due to chronic retinal diseases," said Heiko G. Niessen, PhD, global head of translational medicine, eye health, at Boehringer Ingelheim. "Our collaboration with ZEISS Medical Technology exemplifies our strategy to work with like-minded partners who share our goal of preserving and protecting eyesight and people’s way of life."

Attributes of the ZEISS RDP include the ability for clinicians and researchers to convert their research hypotheses into quantifiable biomarkers and to train their own algorithms and let AI handle complex, time-consuming data analysis, significantly improving efficiency.

The platform will also allow users to aggregate diverse datasets and formats from multiple sources and allow for a more “streamlined research workflow.”

Following a successful pilot phase, the company plans to launch the ZEISS RDP in select countries throughout 2025.

References:

1. ZEISS unveils AI-powered research data platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care. Published May 1, 2025. Accessed May 1, 2025. https://www.zeiss.com/meditec-ag/en/media-news/press-releases/2025/research-data-platform.html